» Articles » PMID: 19936054

Glypican-1 Mediates Both Prion Protein Lipid Raft Association and Disease Isoform Formation

Overview
Journal PLoS Pathog
Specialty Microbiology
Date 2009 Nov 26
PMID 19936054
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

In prion diseases, the cellular form of the prion protein, PrP(C), undergoes a conformational conversion to the infectious isoform, PrP(Sc). PrP(C) associates with lipid rafts through its glycosyl-phosphatidylinositol (GPI) anchor and a region in its N-terminal domain which also binds to heparan sulfate proteoglycans (HSPGs). We show that heparin displaces PrP(C) from rafts and promotes its endocytosis, suggesting that heparin competes with an endogenous raft-resident HSPG for binding to PrP(C). We then utilised a transmembrane-anchored form of PrP (PrP-TM), which is targeted to rafts solely by its N-terminal domain, to show that both heparin and phosphatidylinositol-specific phospholipase C can inhibit its association with detergent-resistant rafts, implying that a GPI-anchored HSPG targets PrP(C) to rafts. Depletion of the major neuronal GPI-anchored HSPG, glypican-1, significantly reduced the raft association of PrP-TM and displaced PrP(C) from rafts, promoting its endocytosis. Glypican-1 and PrP(C) colocalised on the cell surface and both PrP(C) and PrP(Sc) co-immunoprecipitated with glypican-1. Critically, treatment of scrapie-infected N2a cells with glypican-1 siRNA significantly reduced PrP(Sc) formation. In contrast, depletion of glypican-1 did not alter the inhibitory effect of PrP(C) on the beta-secretase cleavage of the Alzheimer's amyloid precursor protein. These data indicate that glypican-1 is a novel cellular cofactor for prion conversion and we propose that it acts as a scaffold facilitating the interaction of PrP(C) and PrP(Sc) in lipid rafts.

Citing Articles

Amyloid, Crohn's disease, and Alzheimer's disease - are they linked?.

Duda-Madej A, Stecko J, Szymanska N, Mietkiewicz A, Szandruk-Bender M Front Cell Infect Microbiol. 2024; 14:1393809.

PMID: 38779559 PMC: 11109451. DOI: 10.3389/fcimb.2024.1393809.


Proteomic Investigation of Differential Interactomes of Glypican 1 and a Putative Disease-Modifying Variant of Ataxia.

Cengiz Winter N, Karakaya M, Mosen P, Brusius I, Anlar B, Haliloglu G J Proteome Res. 2023; 22(9):3081-3095.

PMID: 37585105 PMC: 10476613. DOI: 10.1021/acs.jproteome.3c00402.


Mechanisms of prion-induced toxicity.

Mercer R, Harris D Cell Tissue Res. 2022; 392(1):81-96.

PMID: 36070155 DOI: 10.1007/s00441-022-03683-0.


Novel Polymorphisms and Genetic Characteristics of the Shadow of Prion Protein Gene () in Cats, Hosts of Feline Spongiform Encephalopathy.

Kim Y, Kim H, Kim K, Kim A, Jeong B Viruses. 2022; 14(5).

PMID: 35632724 PMC: 9148082. DOI: 10.3390/v14050981.


Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance.

Loh D, Reiter R Molecules. 2022; 27(3).

PMID: 35163973 PMC: 8839844. DOI: 10.3390/molecules27030705.


References
1.
Hooper N, Turner A . A new take on prions: preventing Alzheimer's disease. Trends Biochem Sci. 2008; 33(4):151-5. DOI: 10.1016/j.tibs.2008.01.004. View

2.
Hooper N . Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae (review). Mol Membr Biol. 1999; 16(2):145-56. DOI: 10.1080/096876899294607. View

3.
Marella M, Lehmann S, Grassi J, Chabry J . Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release. J Biol Chem. 2002; 277(28):25457-64. DOI: 10.1074/jbc.M203248200. View

4.
Caughey B, Baron G . Prions and their partners in crime. Nature. 2006; 443(7113):803-10. DOI: 10.1038/nature05294. View

5.
MEYER R, McKinley M, Bowman K, Braunfeld M, Barry R, Prusiner S . Separation and properties of cellular and scrapie prion proteins. Proc Natl Acad Sci U S A. 1986; 83(8):2310-4. PMC: 323286. DOI: 10.1073/pnas.83.8.2310. View